Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Janice Shipe-Spotloe"'
Autor:
John M. Kirkwood, Alice Chen, David R. Gandara, Janice Shipe-Spotloe, Christopher Ruel, Scott Christensen, Kim A. Margolin, Paul Frankel, Ahmad A. Tarhini
Purpose: Aflibercept is a soluble decoy VEGF receptor and angiogenesis inhibitor with potent preclinical antitumor activity in melanoma. We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::172b4f1e4d57485093f635dd530f9a57
https://doi.org/10.1158/1078-0432.c.6519752.v1
https://doi.org/10.1158/1078-0432.c.6519752.v1
Autor:
John M. Kirkwood, Alice Chen, David R. Gandara, Janice Shipe-Spotloe, Christopher Ruel, Scott Christensen, Kim A. Margolin, Paul Frankel, Ahmad A. Tarhini
PDF file - 17K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a3564662e9d65b028d5792114c04f3
https://doi.org/10.1158/1078-0432.22443278
https://doi.org/10.1158/1078-0432.22443278
Autor:
John M. Kirkwood, Alice Chen, David R. Gandara, Janice Shipe-Spotloe, Christopher Ruel, Scott Christensen, Kim A. Margolin, Paul Frankel, Ahmad A. Tarhini
PDF file - 15K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d098014bb6c4743c55b675bd2b554f9c
https://doi.org/10.1158/1078-0432.22443281
https://doi.org/10.1158/1078-0432.22443281
Autor:
John M. Kirkwood, Alice Chen, David R. Gandara, Janice Shipe-Spotloe, Christopher Ruel, Scott Christensen, Kim A. Margolin, Paul Frankel, Ahmad A. Tarhini
PDF file - 16K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a6dced77c68725a9bc2aca630b76ab
https://doi.org/10.1158/1078-0432.22443284
https://doi.org/10.1158/1078-0432.22443284
Autor:
Paul Frankel, John M. Kirkwood, Janice Shipe-Spotloe, David R. Gandara, Alice P. Chen, Kim Margolin, Scott D Christensen, Christopher Ruel, Ahmad A. Tarhini
Publikováno v:
Clinical Cancer Research. 17:6574-6581
Purpose: Aflibercept is a soluble decoy VEGF receptor and angiogenesis inhibitor with potent preclinical antitumor activity in melanoma. We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::938ea1ee989504c7c23bcb1ef5aef091
https://doi.org/10.1158/1078-0432.ccr-11-1463
https://doi.org/10.1158/1078-0432.ccr-11-1463
Autor:
R. Radkowski, Hussein Tawbi, Ahmad A. Tarhini, F. Viverette, Liza C. Villaruz, Stergios J. Moschos, John M. Kirkwood, M. Sulecki, Janice Shipe-Spotloe
Publikováno v:
British Journal of Cancer
Background: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) reverses the O6-methylguanine (O6-meG) lesion induced by dacarbazine. Depletion of MGMT can be achieved using O6-meG pseudosubstrates. Herein, we report the first phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5d8a6df16bbf61fc5635d291b9b8b79
https://doi.org/10.1038/bjc.2011.285
https://doi.org/10.1038/bjc.2011.285
Autor:
Janice Shipe-Spotloe, Daniel R. Vlock, Michael S. Rabkin, Howard Edington, John M. Kirkwood, Roger Day, Ruth Mascari, Theresa L. Whiteside
Publikováno v:
Cancer. 88:2693-2702
BACKGROUND Antitumor effects of antibodies against ganglioside antigens of melanoma have been reported, but neither optimal doses nor mechanisms have been established. METHODS This Phase IB trial of the murine immunoglobulin IgG3 monoclonal antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15f58f7e0174ce9da76808c004f0fbc8
https://doi.org/10.1002/1097-0142(20000615)88:12<2693::aid-cncr7>3.0.co
https://doi.org/10.1002/1097-0142(20000615)88:12<2693::aid-cncr7>3.0.co
Autor:
John M. Kirkwood, Stergios J. Moschos, Howard Edington, Uma N. M. Rao, Drazen M. Jukic, Janice Shipe-Spotloe, Stephanie R. Land
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(19)
Purpose Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overall survival in patients with high-risk melanoma. However, its mechanism of action is largely unknown. Therefore, HDI was investigated in the neoadjuvant setting to ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d937734903fe80416cec809045a4702
https://pubmed.ncbi.nlm.nih.gov/16809739
https://pubmed.ncbi.nlm.nih.gov/16809739
Publikováno v:
The oncologist. 11(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49ea577cb7caa0a970753753bf27ef60
https://pubmed.ncbi.nlm.nih.gov/16249355
https://pubmed.ncbi.nlm.nih.gov/16249355
Autor:
Janice Shipe-Spotloe, Lori Stover, Catherine M. Bender, Barbara Smelko, Sanjiv S. Agarwala, John M. Kirkwood, Sandra S. Donnelly, Ahmad A. Tarhini
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(17)
PURPOSE: The toxicity associated with adjuvant high-dose interferon-alfa-2b therapy (HDI) for high-risk melanoma can lead to premature discontinuation. It is important to understand the expected adverse events and their underlying mechanisms and to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a59df2abe9533c9f841b09f8df45673
https://pubmed.ncbi.nlm.nih.gov/12202672
https://pubmed.ncbi.nlm.nih.gov/12202672